Skip to main content
KLRA
NASDAQ Life Sciences

Kailera Posts $95.7M Q3 Loss as Obesity Pipeline Hits Full Enrollment

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$12.74
Mkt Cap
$1.659B
52W Low
$9.76
52W High
$28.227
52W Position info
31% above low
Off High info
55% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

KLRA sits 31% above its 52-week low of $9.76.

Summary

Kailera's Q3 net loss widened to $95.7 million from $39.6 million a year earlier, driven by R&D spending that jumped to $84.7 million from $27.0 million as the obesity pipeline scales. Cash, equivalents and marketable securities stood at $1.04 billion at September 30, which the company says funds operations into mid-2028. The quarter's operational news is enrollment: the ribupatide injection Phase 3 KaiNETIC program (~5,000 participants) and the Phase 2b high-dose trial (~260 participants) are both fully enrolled, with data expected mid-2028 and mid-2027 respectively. Kailera also completed an End-of-Phase 2 meeting with the FDA for oral ribupatide and now targets a Phase 3 start in the first half of 2027, while safiglipron Phase 2 data slipped to mid-2027. The cash position and milestone calendar are the substance here; the wider loss is the expected cost of running four programs at once.

At the time of this announcement, KLRA was trading at $12.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.76 to $28.23. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

KLRA - Latest Insights

KLRA
Oct 01, 2026, 6:45 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.20
Real-time Price: $11.58 info
Change: +$0.380 (+3%) info
Market Cap: $1.504B info
KLRA
Aug 12, 2026, 4:29 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.20
Real-time Price: $11.58 info
Change: -$6.62 (-36%) info
Market Cap: $1.504B info
KLRA
Aug 12, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.59
Real-time Price: $11.58 info
Change: -$7.01 (-38%) info
Market Cap: $1.504B info
KLRA
Jul 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $23.97
Real-time Price: $11.58 info
Change: -$12.39 (-52%) info
Market Cap: $1.504B info
KLRA
Jun 05, 2026, 7:40 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $19.37
Real-time Price: $11.58 info
Change: -$7.79 (-40%) info
Market Cap: $1.504B info